comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 04:10:05 - browse：8

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Female surgeons have lower rates of long

WSS

How Vertex's cystic fibrosis drug is changing patients' lives

Peter Marks talks Operation Warp Speed for Rare Diseases

Ukraine and a new approach to mental health in war

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Lasker Awards 2023: Winners in biomedical research

EpiPen alternative approval delay highlights citizen petition issue

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Drug for rare kidney disease narrowly misses mark in clinical trial

The cancer drug shortage isn’t new — and neither are the solutions

FDA panel to weigh approval of NurOwn, controversial ALS drug

The high cost of giving birth even with insurance

EpiPen alternative approval delay highlights citizen petition issue

Anesthesiologist group: stop taking Ozempic before surgery

Ukraine and a new approach to mental health in war

New air purifier tech could be key to improving indoor air quality

Biotech lab space demand falls sharply

focus

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Readout LOUD podcast: possible new ALS drug, artificial wombs

STAT Readout Newsletter: Today in biotech, life science news

Biotech stock slump in 2023: awaiting the turnaround

Researchers CRISPR chickens in bid to protect them from bird flu

Experts study whether long Covid risk adds up with each reinfection

hotspot

leisure time

entertainment

knowledge